HomeCompareFIXX vs SPHD

FIXX vs SPHD: Dividend Comparison 2026

FIXX yields 213.97% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FIXX wins by $177.40M in total portfolio value
10 years
FIXX
FIXX
● Live price
213.97%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.43M
Annual income
$92,441,271.48
Full FIXX calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — FIXX vs SPHD

📍 FIXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIXXSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIXX + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FIXX pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIXX
Annual income on $10K today (after 15% tax)
$18,187.65/yr
After 10yr DRIP, annual income (after tax)
$78,575,080.76/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, FIXX beats the other by $78,574,595.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIXX + SPHD for your $10,000?

FIXX: 50%SPHD: 50%
100% SPHD50/50100% FIXX
Portfolio after 10yr
$88.73M
Annual income
$46,220,921.40/yr
Blended yield
52.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FIXX right now

FIXX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$2.70
+188.9% upside vs current
Range: $2.70 — $2.70
Altman Z
-2.8
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIXX buys
0
SPHD buys
0
No recent congressional trades found for FIXX or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIXXSPHD
Forward yield213.97%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$177.43M$26.5K
Annual income after 10y$92,441,271.48$571.32
Total dividends collected$167.81M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: FIXX vs SPHD ($10,000, DRIP)

YearFIXX PortfolioFIXX Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$32,097$21,397.24$11,133$432.85+$21.0KFIXX
2$98,530$64,186.20$12,363$450.36+$86.2KFIXX
3$289,572$184,144.93$13,695$467.39+$275.9KFIXX
4$815,624$505,782.06$15,138$483.90+$800.5KFIXX
5$2,204,131$1,331,413.21$16,697$499.88+$2.19MFIXX
6$5,721,029$3,362,608.71$18,382$515.31+$5.70MFIXX
7$14,278,479$8,156,977.31$20,198$530.17+$14.26MFIXX
8$34,304,224$19,026,251.97$22,157$544.46+$34.28MFIXX
9$79,425,902$42,720,382.43$24,266$558.18+$79.40MFIXX
10$177,426,987$92,441,271.48$26,536$571.32+$177.40MFIXX

FIXX vs SPHD: Complete Analysis 2026

FIXXStock

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Full FIXX Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this FIXX vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIXX vs SCHDFIXX vs JEPIFIXX vs OFIXX vs KOFIXX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.